Ask AI
Combining Therapeutic Approaches in Metastatic CRPC

CE / CME

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 19, 2025

Expiration: December 18, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on current ASCO guidelines, which of the following best describes the recommended approach to testing for HRR alterations in patients with metastatic prostate cancer?

2.

For a 65-yr-old patient with mCRPC who has progressed after treatment with an ARPI and is found to have a somatic BRCA2 deletion, which of the following would you recommend (assuming all options are easily available)?

3.

A 72-yr-old man presents with de novo metastatic prostate cancer. After initial ADT and docetaxel, he develops castration resistance. He has tissue testing performed and is found to have a PALB2 mutation. Based on current FDA approvals, what treatment would you consider next?

4.

Patient Case: 66-Yr-Old Man With Anemia



  • A 66-yr-old man was diagnosed with T3 by DRE and mpMRI, N1 M1a, low-volume mHSPC

    • Initially managed with ADT alone; declined ARPI at the time

    • PSA began to rise (12 mo: 0.2; 18 mo: 1.2, 24 mo: 14.4)

    • Bone and CT scan: new lesions and progression of lymph nodes

    • Genetic testing identified a pathogenic germline BRCA2 mutation



  • He began a PARP inhibitor + ARPI combination 4 wk ago

    • Now reports fatigue, dizziness with standing, shortness of breath, headache

    • He is diagnosed with grade 3 anemia




In addition to transfusing packed red blood cells, which of the following would you recommend for managing this patient’s grade 3 anemia in your current practice?